How quickly does Wegovy work — and what does progress actually look like?

The real question isn't 'does it work', it's 'when will I feel it?'

This is a question our prescribers hear most weeks, usually phrased with a note of impatience that's entirely understandable. People have often tried other approaches before reaching this point, and they want to know whether the waiting is over.

The honest answer is that Wegovy works on two different timescales. The appetite-regulating effect (feeling full sooner, less preoccupied with food, quieter hunger signals) can start within days of the first injection. That's the GLP-1 pathway doing its job: slowing gastric emptying and shifting the brain's sense of satiety. What takes longer is the weight loss itself, because that requires a sustained calorie deficit that builds over weeks and months.

Most people find the first month relatively modest in terms of scale on the scales. The starting dose of 0.25 mg is a tolerability dose; its job is to let your body adjust, not to produce maximum effect. As the dose steps up (typically through 0.5 mg, 1.0 mg and 1.7 mg toward 2.4 mg maintenance) the effect on appetite deepens. The earliest signs of Wegovy working are often about food noise falling quiet before the numbers on the scales move.

The frame that tends to serve people best: think in quarters, not weeks. By the end of the first three months, many people have lost somewhere between 5% and 8% of their starting weight. That figure grows substantially by the six-month mark and beyond.

What the trial evidence says about the pace of weight loss

The STEP 1 trial (68 weeks, adults with obesity or overweight and at least one weight-related condition, no diabetes) found that participants on semaglutide 2.4 mg lost an average of around 15% of their body weight compared with about 2.4% on placebo. The full STEP 1 results are published in the New England Journal of Medicine and make clear that this is an average: individual results ranged from modest to well above 20%.

The trial data also shows that weight loss isn't linear. The steepest part of the curve tends to come in the middle months, once people reach maintenance dose and the calorie deficit compounds. After around 60 weeks, the curve begins to plateau, which is worth knowing, because it explains why some people worry they've stopped responding when they're actually at or near their maximum benefit.

A higher maintenance dose matters too. The MHRA approved a 7.2 mg Wegovy pen in April 2026, following data showing average losses of around 20.7% over 72 weeks at that dose, closer to the results seen with tirzepatide. If you want a broader look at how long Wegovy takes to produce its full effect, the evidence points clearly to the six-to-twelve-month window as where the most significant change occurs.

One practical point: the NHS's own guidance notes that if less than 5% of body weight is lost after six months on the maintenance dose, continuing treatment should be reviewed. That threshold is a clinical checkpoint, not a prediction, but it's worth knowing it exists. NICE's appraisal of semaglutide for weight management (TA875) outlines this clearly.

Factors that shape your personal timeline

The trial averages are real, but they're population figures. Several things influence how quickly Wegovy works for any one person.

Starting weight matters, people with higher BMIs tend to see larger absolute losses, though the percentage figure can be similar. Dose tolerance plays a role too: people who experience significant nausea during titration may need to hold at a lower dose longer, which delays the point at which the full effect kicks in. That's not a failure; it's the prescriber and patient making a sensible call together.

Lifestyle factors have a genuine effect. Wegovy is licensed alongside a reduced-calorie diet and increased physical activity, those elements aren't optional extras. The medicine reduces appetite, but the deficit still needs to be there. Protein intake and staying well hydrated also matter, particularly as the dose increases and appetite suppression is at its strongest.

For a broader look at how semaglutide-based medicines work as a class, including how the GLP-1 mechanism produces its effects, there's more detail in our related content. And if you're weighing up treatment options more broadly, the weight-loss treatments overview covers the licensed medicines available through nume.

Sleep, stress and underlying metabolic conditions (thyroid function, insulin resistance) can all modify the pace of response. None of these are reasons not to try; they're reasons to have a thorough clinical assessment before starting, and ongoing support while you're on treatment.

When to consider stopping, and what comes next

The question of when to stop Wegovy is genuinely important and often underplanned. Weight tends to return if treatment stops without lifestyle changes being embedded, the trial evidence on this is consistent. Wegovy is not a short course; the decision to stop is a clinical one, made with your prescriber once you've reached a stable weight and have sustainable habits in place.

The NICE recommendation for semaglutide under TA875 includes a maximum treatment duration of two years within NHS specialist services. Private prescriptions don't carry the same fixed ceiling, but good clinical practice still involves regular review. At nume, every repeat order goes through a fresh clinical review, the same prescriber oversight that applies at the start applies throughout.

If your weight loss has stalled and you're wondering whether you've reached your plateau or whether something needs adjusting, that's a conversation for your prescriber rather than a reason to stop independently. The full Wegovy treatment overview covers what ongoing management looks like, and our frequently asked questions page picks up many of the practical queries that come up during treatment. For context on what treatment costs through a private route, the Wegovy cost page sets out what's included in a transparent price.